Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.

Kodak CEO Jim Continenza is revealing nothing about ongoing investigations, which leave Kodak’s plans to venture into pharmaceuticals – along with a $765m federal loan – uncertain.

Fujifilm has successfully transformed its business strategy by expanding away from traditional photographic film and toward new priority business fields – significantly in regenerative medicine. Identifying health care as a key growth area, Fujifilm targets the role of being a comprehensive provider in the fields of prevention, diagnosis and treatment.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November through December 2013